The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Open accessAbstract
Triantennary N-acetyl galactosamine (GalNAc, GN3), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), enhances the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6–10-fold in mouse liver. When combined with next-generation ASO designs comprised of short S-cEt (S-2′-O-Et-2′,4′-bridged nucleic acid) gapmer ASOs, ∼60-fold enhancement in potency relative to the parent MOE (2′-O-methoxyethyl RNA) ASO was observed. GN3-conjugated ASOs showed high affinity for mouse ASGPR, which results in enhanced ASO delivery to hepatocytes versus non-parenchymal cells. After internalization into cells, the GN3-ASO conjugate is metabolized to liberate the parent ASO in the liver. No metabolism of the GN3-ASO conjugate was detected in plasma suggesting that GN3 acts as a hepatocyte targeting prodrug that is detached from the ASO by metabolism after internalization into the liver. GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice. The unconjugated ASOs are currently in late stage clinical trials for the treatment of familial chylomicronemia and TTR-mediated polyneuropathy. The ability to translate these observations in humans offers the potential to improve therapeutic index, reduce cost of therapy and support a monthly dosing schedule for therapeutic suppression of gene expression in the liver using ASOs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Self-citationGeuze, H. J., Slot, J. W., Strous, G. J. A. M., Lodish, H. F., & Schwartz, A. L. (1983) · Cell · doi:10.1016/0092-8674(83)90518-4 · Cited by 816
The Isolation and Properties of a Rabbit Liver Binding Protein Specific for Asialoglycoproteins
Hudgin, R. L., Pricer, W. E., Ashwell, G., Stockert, R. J., & Morell, A. G. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)79761-9 · Cited by 615
Carbohydrates in Chemistry and Biology
Ernst, B., Hart, G. W., & Sinaý, P. (2000) · Wiley eBooks · doi:10.1002/9783527618255 · Cited by 594
The asialoglycoprotein receptor: relationships between structure, function, and expression
Stockert, R. J. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.591 · Cited by 520
The asialoglycoprotein receptor: a model for endocytic transport receptors
Spiess, M. (1990) · Biochemistry · doi:10.1021/bi00495a001 · Cited by 485
Phosphorothioate Oligodeoxynucleotides: What Is Their Origin and What Is Unique About Them?
ECKSTEIN, F. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.117 · Cited by 382
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
Self-citationPlank, C., Zatloukal, K., Cotten, M., Mechtler, K., & Wagner, E. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00018a012 · Cited by 324
Antisense oligonucleotide pharmacokinetics and metabolism
Geary, R. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902877680 · Cited by 300
Antisense Drug Technology: Principles: Strategies, and Applications
(2021) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 268
Seth, P. P., Siwkowski, A., Allerson, C. R., Vasquez, G., Lee, S., Prakash, T. P., Wancewicz, E. V., Witchell, D., & Swayze, E. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801294h · Cited by 266
Self-citationHuman hepatic lectin. Physiochemical properties and specificity.
Baenziger, J. U., & Maynard, Y. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85538-2 · Cited by 264
WHO Expert Committee on Specifications for Pharmaceutical Preparations.
Yin, H., Hetzke, J., Kozarewicz, P., Gould, A., Vallender, M., Suffolk, B., Hoek, A., Addae‐Mensah, I., Mehmandoust, M., Rabouhans, M. L., et al. (1969) · PubMed · Cited by 261
Straarup, E. M., Fisker, N., Hedtjärn, M., Lindholm, M. W., Rosenbohm, C., Aarup, V., Hansen, H. F., Ørum, H., Hansen, J. B. R., & Koch, T. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq457 · Cited by 249
Rensen, P. C. N., Sliedregt, L. A. J. M., Ferns, M., Kieviet, E., van Rossenberg, S. M. W., van Leeuwen, S. H., van Berkel, T. J. C., & Biessen, E. A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101786200 · Cited by 231
Seth, P. P., Vasquez, G., Allerson, C. A., Berdeja, A., Gaus, H., Kinberger, G. A., Prakash, T. P., Migawa, M. T., Bhat, B., & Swayze, E. E. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo902560f · Cited by 211
Self-citationZhang, H., Löwenberg, E. C., Crosby, J. R., MacLeod, A. R., Zhao, C., Gao, D., Black, C., Revenko, A. S., Meijers, J. C. M., Stroes, E. S., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277798 · Cited by 203
Self-citationMeier, M., Bider, M. D., Malashkevich, V. N., Spiess, M., & Burkhard, P. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3853 · Cited by 182
Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA.
Manoharan, M., Egli, M., Teplova, M., Minasov, G., Tereshko, V. A., Inamati, G. B., & Cook, P. D. (1999) · Nature Structural Biology · doi:10.1038/9304 · Cited by 178
Crooke, S. T., & Geary, R. S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04469.x · Cited by 171
Bijsterbosch, M. K. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.16.3290 · Cited by 154
Synthesis of Cluster Galactosides with High Affinity for the Hepatic Asialoglycoprotein Receptor
Biessen, E. A. L., Beuting, D. M., Roelen, H. C. P. F., van der MAREL, G. A., BOOM, J. H. V., & van Berkel, T. J. C. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00009a014 · Cited by 151
Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides
Benson, M. D., Kluve‐Beckerman, B., Zeldenrust, S. R., Siesky, A. M., Bodenmiller, D. M., Showalter, A. D., & Sloop, K. W. (2006) · Muscle & Nerve · doi:10.1002/mus.20503 · Cited by 150
Graham, M. J., Crooke, S. T., Monteith, D., Cooper, S. R., Lemonidis, K. M., Stecker, K., Martin, M. J., & Crooke, R. M. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37605-0 · Cited by 140
Self-citationAckermann, E. J., Guo, S., Booten, S. L., Alvarado, L., Benson, M. D., Hughes, S. G., & Monia, B. P. (2012) · Amyloid · doi:10.3109/13506129.2012.673140 · Cited by 139
Self-citationClinical pharmacokinetics of second generation antisense oligonucleotides
Yu, R. Z., Grundy, J. S., & Geary, R. S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.737320 · Cited by 136
Juliano, R. L., Ming, X., Carver, K. A., & Laing, B. M. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0463 · Cited by 135
Steirer, L. M., Park, E. I., Townsend, R. R., & Baenziger, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m808689200 · Cited by 128
Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates
Crosby, J. R., Marzec, U. M., Revenko, A. S., Zhao, C., Gao, D., Matafonov, A., Gailani, D., MacLeod, A. R., Tucker, E. I., Gruber, A., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301282 · Cited by 128
Self-citationYu, R. Z., Lemonidis, K. M., Graham, M. J., Matson, J. E., Crooke, R. M., Tribble, D. L., Wedel, M. K., Levin, A. A., & Geary, R. S. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.005 · Cited by 125
Self-citationMarcusson, E. G. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.8.2016 · Cited by 123
Liver as a target for oligonucleotide therapeutics
Sehgal, A., Vaishnaw, A. K., & Fitzgerald, K. J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.045 · Cited by 116
Sample preparation method for isolation of single‐cell types from mouse liver for proteomic studies
Liu, W., Hou, Y., Chen, H., Wei, H., Lin, W., Li, J., Zhang, M., He, F., & Jiang, Y. (2011) · PROTEOMICS · doi:10.1002/pmic.201100157 · Cited by 102
Rensen, P. C. N., van Leeuwen, S. H., Sliedregt, L. A. J. M., van Berkel, T. J. C., & Biessen, E. A. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049481d · Cited by 87
Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor
Grewal, P. K., Aziz, P. V., Uchiyama, S., Rubio, G. R., Lardone, R. D., Le, D., Varki, N. M., Nizet, V., & Marth, J. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313905110 · Cited by 83
Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo
Biessen, E. A. L., Vietsch, H., Rump, E. T., Fluiter, K., Kuiper, J., Bijsterbosch, M. K., & van Berkel, T. J. C. (1999) · Biochemical Journal · doi:10.1042/bj3400783 · Cited by 82
Murray, S., Ittig, D., Koller, E., Berdeja, A., Chappell, A., Prakash, T. P., Norrbom, M., Swayze, E., Leumann, C., & Seth, P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks273 · Cited by 82
Self-citationAntisense oligonucleotide treatment ameliorates alpha-1 antitrypsin–related liver disease in mice
Guo, S., Booten, S. L., Aghajan, M., Hung, G., Zhao, C., Blomenkamp, K., Gattis, D., Watt, A. T., Freier, S. M., Teckman, J. H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67968 · Cited by 79
Self-citationEgli, M., Pallan, P. S., Allerson, C. R., Prakash, T. P., Berdeja, A., Yu, J., Lee, S. S., Watt, A. T., Gaus, H. J., Bhat, B., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja207086x · Cited by 72
Self-citationButler, M., Crooke, R. M., Graham, M. J., Lemonidis, K. M., Lougheed, M., Murray, S. F., Witchell, D. R., Steinbrecher, U. P., & Bennett, C. F. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35317-0 · Cited by 72
Self-citationGraham, M. J., Crooke, S. T., Lemonidis, K. M., Gaus, H. J., Templin, M. V., & Crooke, R. M. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00669-4 · Cited by 45
Self-citationDuff, R. J., Deamond, S. F., Roby, C. D., Zhou, Y., & Ts’o, P. O. P. (2000) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(00)13019-8 · Cited by 24
Interactions of Oligosaccharides and Glycopeptides with Hepatic Carbohydrate Receptors
Lee, Y. C., & Lee, R. T. (2000) · Carbohydrates in Chemistry and Biology · doi:10.1002/9783527618255.ch72 · Cited by 11
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Metadata
- Authors
- Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., Riney, S., Booten, S. L., Murray, S. F., Gaus, H., Crosby, J., Lima, W. F., Guo, S., Monia, B. P., Swayze, E. E., & Seth, P. P.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-03
- Volume
- 42
- Issue
- 13
- Pages
- 8796-8807
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2018328995
- Cited by
- 610
- References
- 44
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.